Production process analysis: a review of the device history record confirmed that the device was manufactured and tested according to relevant procedures, and shipped according to manufacturer's specifications.User (surgeon and patient) information analysis: patient #(b)(6) (pas #(b)(6)) index procedure was performed on (b)(6) 2021.On 14-mar-2023, apifix was notified that patient #(b)(6) (pas #(b)(6)) underwent removal of the device on (b)(6) 2023 due to the rod reaching maximum elongation and increased cobb angle.The site reported that they may reinstrument in the future but for now they are going to follow the patient's curve.Clinical affairs review of case information identified that the patient was treated outside of indications, specifically the patient's pre-op primary curve was measured (per pssg: pediatric spine study group) at 63°.The apifix mid-c system is indicated for use in patients having a cobb angle of 35 to 60 degrees.Reoperation events are a known risk that was assessed and recorded by the product risk management file.The risk of curve progression has been assessed and found to be acceptable.The current rate for all relevant criteria (curve progression, insufficient curve correction, imbalance) is in line with the rate reported in the literature for this type of complication as described in the company's cer (clinical evaluation report).The risk has been quantified, characterized, and documented as acceptable within a full risk assessment.Apifix is closing this complaint, but will continue to monitor this 'failure mode'; complaint trending will continue to monitor per post marketing surveillance procedure.If any further relevant information is identified, the complaint file will be reopened and a supplemental medwatch will be filed.
|